Pfizer Corporation

Warner-lambert Company

Merck + Co., Inc.

Cayman Chemical Company Incorporated

Nancy Sue Barta

David Juergen Wustrow

Jacob Bradley Schwarz

Andrew John Thorpe

Stephen Douglas Barrett

Robert D Larsen

Christopher Franklin Bigge

Gregory William Endres

Gregory A Reichard

Andriy Kornilov

Steven A Weissman

Shelly Ann Glase

Kirk M Maxey

Adam Uzieblo

Daniel Richard Sidler

David L Gray

Norman Lloyd Colbry

Zhijian Zhu

Raymond Hudack, Jr

Kristin Knapp Lin

Lloyd Jerome Simons

Wenijan Xu

A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

Prostaglandin E1 and E2 analogs for the treatment of various medical conditions

This invention relates to compounds of the formulae I wherein R-R, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

Substituted morpholine compounds for the treatment of central nervous system disorders

This invention relates to novel tetrazole and oxadiazalone &#x3b2;-amino acids derivatives of the formula wherein G is wherein Rthrough Rare defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl &#x3b2;-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (&#x3b1;2&#x3b4; ligands). Such compounds have affinity for the &#x3b1;2&#x3b4; subunit of a calcium channel.

Tetrazole and oxadiazolone substituted &#x3b2;-amino acid derivatives

This invention relates to certain &#x3b2;-amino acids that bind to the alpha-2-delta (&#x3b1;2&#x3b4;) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Amino acids with affinity for the &#x3b1;-2-delta-protein

The present invention provides compounds of Formula (I) and a method of treating Alzheimer's disease using a compound of Formula (I), wherein: Rand Rinclude alkyl and phenylalkyl; Ris hydrogen or alkyl; and Rand Rinclude alkyl, alkoxy, carboxyl, alkoxycarbonyl, and nitro. Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of Formula (I)and a method of imaging amyloid deposits using compounds of Formula (I).

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives

A process for preparing a &bgr;-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalyst, a co-oxidant selected from a halohydantoin, a haloisocyanuric acid, and an alkali metal salt of a haloisocyanuric acid, and optionally an asymmetric ligand, to form a reaction mixture containing the &bgr;-hydroxy carbamate product. The process optionally further comprises treating the &bgr;-hydroxy carbamate product with additional base to form an oxazolidinone. The oxazolidinones are useful as chiral auxiliary agents and as intermediates for the formation of pharmaceutically active substances such as alpha 1 a adrenergic receptor antagonists. A process for preparing nitrogen-functionalized derivatives of the oxazolidinones is also disclosed.

Process for preparing &bgr;-hydroxycarbamates and their conversion to oxazolidinones

Growing community of inventors

Brighton, MI, United States of America

Nancy Sue Barta